David Walde

7.7k citations
22 papers · 4.8k · 2 hit papers · h-index 16

Impact in

  • Oncology top 0.5%
    • Pancreatic and Hepatic Oncology Research
    • Colorectal Cancer Treatments and Studies
    • Cancer Treatment and Pharmacology
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Treatment and Pharmacology 6
    • Colorectal Cancer Treatments and Studies 3
    • Lung Cancer Research Studies 3
    • Pancreatic and Hepatic Oncology Research 3
    • Nausea and vomiting management 5

David Walde

22 papers receiving 4.6k citations

David Walde's Hit Papers

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group 2007 · 2.9k citations
2.9k0+8+16Years since publication50010001.5k2.0k2.5k

Peers

David Walde
Comparison fields: 5 of 113
  • Oncology 3.7k
  • Cancer Research 1.0k
  • Pulmonary and Respiratory Medicine 1.4k
  • Hepatology 303
  • Surgery 901
Replace John Hamm with:
John Hamm United States
Connie Stephens United States
P. Murawa Poland
Stefan Boeck Germany
Henry Q. Xiong United States
Ryan Nelson United States
Faiza Khemissa-Akouz France
Jorge Barriuso United Kingdom
Markus Borner Switzerland
Mark Kozloff United States
David Walde relative to John Hamm United States John Hamm's profile →
Citations per field
00.5×1.5×
John Hamm · 1×
Citations per year

Countries citing papers authored by David Walde

Since Specialization
Citations

This map shows the geographic impact of David Walde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Walde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Walde more than expected).

Fields of papers citing papers by David Walde

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Walde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Walde. The network helps show where David Walde may publish in the future.

Co-authors

The 25 scholars most cited alongside David Walde, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Walde Line = papers co-authored together David Walde links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
Hit paper breakdown →
20072909
2
Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study
Hit paper breakdown →
2001882
3 2009186
4 199893
5 199987
6 199784
7 200873
8 201166
9 200658
10 201154
11 199754
12 201047
13 201040
14 197138
15 199537
16
Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
199532
17 202315
18 20078
19 19996
20 19915

About David Walde

David Walde is a scholar working on Oncology, Surgery, Physiology, Pulmonary and Respiratory Medicine and Epidemiology, having authored 22 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (6 papers), Nausea and vomiting management (5 papers), Neuroendocrine Tumor Research Advances (4 papers), Colorectal Cancer Treatments and Studies (3 papers), Pathogenesis and Treatment of Hiccups (3 papers), Lung Cancer Research Studies (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). The work is most often cited by research in Oncology (3.7k citations), Cancer Research (1.0k citations), Pulmonary and Respiratory Medicine (1.4k citations), Hepatology (303 citations) and Surgery (901 citations). David Walde has collaborated with scholars based in Canada, United States and New Zealand. Frequent co-authors include Keyue Ding, Malcolm J. Moore, H. Au, Robert Lim, Steven Gallinger, Wendy R. Parulekar, P. Murawa, Robert A. Wolff, J. Randolph Hecht and Gary M. Clark. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Investigational New Drugs, British Journal of Haematology and Lung Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact